欧洲呼吸学会肺泡蛋白沉积症诊断与管理指南
该指南由欧洲呼吸学会工作组制定,采用GRADE方法系统评价文献,针对肺泡蛋白沉积症(PAP)提出5个PICO问题和2个叙述性问题的推荐。PAP诊断基于CT和BAL细胞学或肺组织学,明确病因需GM-CSF抗体检测或基因分析。治疗包括全肺灌洗、GM-CSF增强治疗等,但支持证据仍有限。
要点
- PAP诊断基于CT和BAL细胞学或肺组织学
- 明确PAP病因需GM-CSF抗体检测或基因分析
- 治疗可选全肺灌洗和GM-CSF增强治疗等
核心结论
- PAP诊断基于CT和BAL细胞学或肺组织学,明确病因需GM-CSF抗体检测或基因分析。
- PAP有多种治疗选择包括全肺灌洗和GM-CSF增强治疗,但支持证据仍有限。
研究设计与样本
- 欧洲呼吸学会工作组由临床医生、方法学家和PAP患者组成,遵循ERS临床实践指南手册和GRADE方法制定推荐。
主要发现
- 工作组针对5个PICO问题制定了关于全肺灌洗、GM-CSF增强治疗、利妥昔单抗、血浆置换和肺移植的推荐。
- 基于叙述性问题,工作组就GM-CSF抗体检测、诊断性BAL和活检的使用提出了推荐。
- 工作组还提供了诊断干预和治疗层级的信息。
关键数值与推荐
- PAP诊断基于CT和BAL细胞学或肺组织学。
- 特定PAP病因诊断需GM-CSF抗体检测或基因分析。
- 治疗选项包括全肺灌洗和GM-CSF增强治疗等,但支持证据有限。
临床怎么用
- 临床医生可依据CT和BAL细胞学或肺组织学诊断PAP,并通过GM-CSF抗体检测或基因分析明确病因。
- 全肺灌洗和GM-CSF增强治疗可用于PAP管理,但需知晓支持证据有限。
局限性
- 支持PAP治疗的证据仍然有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary alveolar proteinosis (PAP) is a rare syndrome caused by several distinct diseases leading to progressive dyspnoea, hypoxaemia, risk of respiratory failure and early death due to accumulation of proteinaceous material in the lungs. Diagnostic strategies may include computed tomography (CT) of the lungs, bronchoalveolar lavage (BAL), evaluation of antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), genetic testing and, eventually, lung biopsy. The management options are focused on removing the proteinaceous material by whole lung lavage (WLL), augmentation therapy with GM-CSF, rituximab, plasmapheresis and lung transplantation. The presented diagnostic and management guidelines aim to provide guidance to physicians managing patients with PAP. METHODS: A European Respiratory Society Task Force composed of clinicians, methodologists and patients with experience in PAP developed recommendations in accordance with the ERS Handbook for Clinical Practice Guidelines and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. This included a systematic review of the literature and application of the GRADE approach to assess the certainty of evidence and strength of recommendations. The Task Force formulated five PICO (Patients, Intervention, Comparison, Outcomes) questions and two narrative questions to develop specific evidence-based recommendations. RESULTS: The Task Force developed recommendations for the five PICO questions. These included management of PAP with WLL, GM-CSF augmentation therapy, rituximab, plasmapheresis and lung transplantation. Also, the Task Force made recommendations regarding the use of GM-CSF antibody testing, diagnostic BAL and biopsy based on the narrative questions. In addition to the recommendations, the Task Force provided information on the hierarchy of diagnostic interventions and therapy. CONCLUSIONS: The diagnosis of PAP is based on CT and BAL cytology or lung histology, whereas the diagnosis of specific PAP-causing diseases requires GM-CSF antibody testing or genetic analysis. There are several therapies including WLL and augmentation therapy with GM-CSF available to treat PAP, but supporting evidence is still limited.
引用
- McCarthy C, Bonella F, O'Callaghan M, et al. European Respiratory Society guidelines for the diagnosis and management of pulmonary alveolar proteinosis. Eur Respir J. 2024. PMID: 39147411. doi:10.1183/13993003.00725-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。